VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2016

Summary

Vertex Pharmaceuticals Inc. reported a net loss of $38.8 million for the third quarter of 2016, a significant improvement from a net loss of $95.1 million in the same period last year. This improvement was driven by a substantial increase in total revenues, which grew by 34% to $413.8 million, primarily fueled by strong growth in product revenues. ORKAMBI and KALYDECO were the key drivers, with ORKAMBI revenue increasing by 79% to $234.0 million and KALYDECO revenue growing by 6% to $175.6 million. Despite the revenue growth, operating costs and expenses also increased, by 14% to $432.5 million, largely due to higher research and development and cost of product revenues. The company continues to invest heavily in its pipeline, particularly in cystic fibrosis therapies. Looking ahead, Vertex anticipates continued revenue growth from its approved products and progress in its extensive clinical development programs, aiming to solidify its position in the CF market and explore new therapeutic areas.

Key Highlights

• 1Total revenues increased by 34% year-over-year to $413.8 million, driven by robust product sales.
• 2Net loss attributable to Vertex narrowed significantly to $38.8 million from $95.1 million in the prior year's quarter.
• 3ORKAMBI product revenues saw substantial growth, increasing by 79% to $234.0 million.
• 4KALYDECO product revenues also increased, by 6% to $175.6 million.
• 5Research and development expenses increased by 11% to $272.4 million, reflecting continued investment in pipeline development.
• 6Sales, general and administrative expenses rose by 6% to $106.1 million, supporting commercial efforts.
• 7The company ended the quarter with $1.13 billion in cash, cash equivalents, and marketable securities, indicating a strong liquidity position.

Frequently Asked Questions